MATINAS BIOPHARMA HOLDINGS I (MTNB) Stock Price & Overview
NYSEARCA:MTNB • US5768103039
The current stock price of MTNB is 0.5899 USD. Today MTNB is down by -2.25%. In the past month the price increased by 2.27%. In the past year, price increased by 9.33%.
MTNB Key Statistics
- Market Cap
- 3.781M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.17
- Dividend Yield
- N/A
MTNB Stock Performance
MTNB Stock Chart
MTNB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MTNB. When comparing the yearly performance of all stocks, MTNB is a bad performer in the overall market: 76.92% of all stocks are doing better.
MTNB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MTNB. MTNB has a bad profitability rating. Also its financial health evaluation is rather negative.
MTNB Earnings
MTNB Forecast & Estimates
MTNB Groups
Sector & Classification
MTNB Financial Highlights
Over the last trailing twelve months MTNB reported a non-GAAP Earnings per Share(EPS) of -4.17. The EPS increased by 24.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -212.28% | ||
| ROE | -315.97% | ||
| Debt/Equity | 0 |
MTNB Ownership
MTNB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.73 | 417.437B | ||
| AMGN | AMGEN INC | 16.24 | 204.229B | ||
| GILD | GILEAD SCIENCES INC | 16.16 | 183.894B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.72 | 121.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.46 | 83.255B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.33 | 43.24B | ||
| INSM | INSMED INC | N/A | 31.965B | ||
| NTRA | NATERA INC | N/A | 28.775B | ||
| BIIB | BIOGEN INC | 12.28 | 27.876B | ||
| MRNA | MODERNA INC | N/A | 22.581B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.26 | 21.486B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.053B | ||
| EXAS | EXACT SCIENCES CORP | 309.39 | 19.749B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MTNB
Company Profile
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 3 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Company Info
MATINAS BIOPHARMA HOLDINGS I
Suite 302, 1545 Route 206 South
Bedminster NEW JERSEY 07921 US
CEO: Jerome D. Jabbour
Employees: 3
Phone: 19084431860
MATINAS BIOPHARMA HOLDINGS I / MTNB FAQ
Can you describe the business of MATINAS BIOPHARMA HOLDINGS I?
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Bedminster, New Jersey and currently employs 3 full-time employees. The company went IPO on 2014-06-03. The firm is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Can you provide the latest stock price for MATINAS BIOPHARMA HOLDINGS I?
The current stock price of MTNB is 0.5899 USD. The price decreased by -2.25% in the last trading session.
What is the dividend status of MATINAS BIOPHARMA HOLDINGS I?
MTNB does not pay a dividend.
What is the ChartMill technical and fundamental rating of MTNB stock?
MTNB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the employee count for MTNB stock?
MATINAS BIOPHARMA HOLDINGS I (MTNB) currently has 3 employees.
Can you provide the short interest for MTNB stock?
The outstanding short interest for MATINAS BIOPHARMA HOLDINGS I (MTNB) is 0.11% of its float.